

A *Toxoplasma gondii* phosphoinositide phospholipase C (*TgPI-PLC*) with high affinity for phosphatidylinositol

Jianmin FANG*, Norma MARCHESINI† and Silvia N. J. MORENO*^{†1}

*Department of Cellular Biology, and Center for Tropical and Emerging Global Diseases, The University of Georgia, Athens, GA 30602, U.S.A., and †Laboratory of Molecular Parasitology, Department of Pathobiology and Center for Zoonoses Research, University of Illinois at Urbana-Champaign, Urbana, IL 61802, U.S.A.

The *Toxoplasma gondii* phosphoinositide-specific phospholipase C gene (*TgPI-PLC*) was cloned, sequenced and expressed in *Escherichia coli* and its enzymatic characteristics were investigated. *TgPI-PLC* is present in the genome as a single-copy gene consisting of 22 exons interrupted by 21 introns, and encodes a polypeptide of 1097 amino acids with a predicted molecular mass of 121 kDa. In addition to the conserved catalytic X and Y domains, *TgPI-PLC* contains an apparent N-terminal PH domain, an EF hand motif and a C-terminal C2 domain. When compared with mammalian δ -type PI-PLC, *TgPI-PLC* has an additional extended N-terminus and two insertions in the region between the X and Y domains, with a 31–35% identity over the whole

sequence. Recombinant *TgPI-PLC*, as well as the native enzyme obtained from crude membrane extracts of the parasite, was more active with phosphatidylinositol than with phosphatidylinositol 4,5-bisphosphate as substrate. Indirect immunofluorescence analysis using an affinity-purified antibody against *TgPI-PLC* revealed that this enzyme localizes in the plasma membrane of the parasites.

Key words: calcium, inositol 1,4,5-trisphosphate, phosphatidylinositol 4,5-bisphosphate, phosphoinositide, phospholipase C (PLC), *Toxoplasma gondii*.

INTRODUCTION

PI-PLCs (phosphoinositide-specific phospholipases C) catalyse the hydrolysis of PIP₂ (phosphatidylinositol 4,5-bisphosphate) to IP₃ (D-*myo*-inositol 1,4,5-trisphosphate) and DAG (*sn*-1,2-diacylglycerol) [1,2]. The products of this reaction function as second messengers in eukaryotic cells. The soluble IP₃ stimulates release of Ca²⁺ from intracellular stores [1]. The membrane-resident DAG stimulates protein phosphorylation by activating various protein kinase C isoenzymes [2]. So far, 13 mammalian PI-PLC isoenzymes have been cloned, and they are divided into six classes (β -, γ -, δ -, ϵ -, ζ - and η -type) on the basis of their structure and activation mechanism [3]. It seems very likely that PI-PLC- δ evolved first, because every PI-PLC cloned so far from a non-mammalian species (for example *Dictyostelium*, yeast, higher plants, *Chlamydomonas*) is a δ -isoform [4]. Results from several laboratory groups [5–8] have suggested that, at least in yeasts, PI-PLC- δ is required for a number of nutritional and stress-related responses. It has also been postulated that PI-PLC- δ could have a role in differentiation of *Dictyostelium discoideum* [9]. Transcription of this PI-PLC- δ appears to be enhanced during cell aggregation, decreases during slug formation and increases in the culminating fruit body [9]. *D. discoideum* PI-PLC- δ is G-protein-coupled [10].

The knowledge of the functions of PI-PLCs in parasitic protozoa is very limited. In *Trypanosoma cruzi*, a novel lipid-modified PI-PLC [11] is involved in the differentiation of trypomastigote to amastigote forms [12] and has also been postulated to be

involved in the removal of GPI (glycosylphosphatidylinositol)-anchored proteins [13]. Roles for a PI-PLC in both *Toxoplasma gondii* invasion and egress from the host cells have been proposed [14–16]. Ethanol, which is a potent trigger of Ca²⁺-stimulated microneme secretion [14], stimulated an increase in *T. gondii* IP₃, implying that this second messenger may mediate intracellular Ca²⁺ release [15]. Consistent with this observation, xestospongine C, an IP₃ receptor antagonist, inhibited microneme secretion and blocked parasite attachment and invasion of host cells [15]. It was proposed that *T. gondii* possesses an intracellular Ca²⁺ release channel with properties of the IP₃/ryanodine receptor superfamily [15]. A role for a *T. gondii* PI-PLC in parasite egress from the dying host has also been postulated on the basis of studies with the PI-PLC inhibitor U-73122 [16]. It was shown that permeabilized *Toxoplasma*-infected cells pre-incubated with U-73122, but not with the inactive analogue U-73343, prevented parasite egress in the presence of extracellular buffer, and that parasite egress depended on the intracellular Ca²⁺ increase stimulated by the decrease in the external K⁺ concentration [16].

In the present paper, we report the cloning, sequencing, and expression of a gene (*TgPI-PLC*) encoding a PI-PLC from *T. gondii*. The gene product (*TgPI-PLC*) was found to be associated with the plasma membrane. The enzyme is similar to δ -type PI-PLCs of mammals and plants, but, in contrast with other PI-PLCs, when tested under some specific conditions of Ca²⁺ and Mg²⁺ concentrations, it is more active against PI (phosphatidylinositol) than against PIP₂.

Abbreviations used: DAG, diacylglycerol; GPI, glycosylphosphatidylinositol; HFF, human foreskin fibroblast; IP₃, D-*myo*-inositol 1,4,5-trisphosphate; IPTG, isopropyl β -D-thiogalactoside; NES, nuclear export signal; ORF, open reading frame; PBS-T, PBS containing 0.1% Tween 20; PH, pleckstrin homology; PI, phosphatidylinositol; PIP₂, phosphatidylinositol 4,5-bisphosphate; PI-PLC, phosphoinositide-specific phospholipase C; *TgPI-PLC*, *Toxoplasma gondii* PI-PLC; r*TgPI-PLC*, recombinant *TgPI-PLC*; PLC, phospholipase C; RIPA, radioimmunoprecipitation analysis; SAG1, surface antigen 1; sulpho-NHS-biotin, sulphonyl-N-hydroxysuccinimidobiotin.

¹ To whom correspondence should be addressed (email smoreno@uga.edu).

The nucleotide sequence data for *TgPI-PLC* and *Trypanosoma brucei* PI-PLC were deposited in DDBJ, EMBL, GenBank® and GSDB Nucleotide Sequence Databases under accession numbers AY304575 and AY157307 respectively.

MATERIALS AND METHODS

Cultures

T. gondii tachyzoites (RH and 2F1 strains) were cultivated in primary HFFs (human foreskin fibroblasts) maintained in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10 % foetal calf serum (HyClone) and an antibiotic mixture of penicillin and streptomycin, at 37 °C and 5 % CO₂, and purified as described by Moreno and Zhong [17]. The transgenic 2F1 strain stably expressing the β -galactosidase gene was a gift from Dr L. David Sibley (Washington University School of Medicine, St. Louis, MO, U.S.A.).

Isolation of cDNA and genomic DNA clones of *TgPI-PLC* and sequencing

Using *Trypanosoma cruzi PI-PLC* (GenBank® accession number AF093565) to search the *T. gondii* genome database (<http://ToxoDB.org/>) [18], DNA contig sequences ranging from 100 to 300 bp were found to be highly similar to *Trypanosoma cruzi PI-PLC*. Specific primers against these shorter fragments were used to amplify *T. gondii* cDNA by PCR in a PTC-100 Programmable Thermal Controller (MJ Research), and resulted in a unique 1.3 kb PCR product, which subsequently was cloned into pCR 2.1-TOPO vector (Invitrogen Life Technologies) and sequenced. A BLAST search of the GenBank® database revealed that this 1.3 kb cDNA clone (Ta1.3) encoded a protein fragment with high identity with other known PLCs. Subsequently the Ta1.3 clone was used as a DNA probe to screen *T. gondii* tachyzoite cDNA and genomic libraries (both kindly provided by the AIDS Reference and Reagent Repository, U.S. National Institutes of Health, Bethesda, MD, U.S.A.). Approx. 2×10^6 plaques of the cDNA library were screened using [α -³²P]dCTP-labelled Ta1.3. Three positive cDNA clones were obtained, and subsequent DNA sequencing confirmed that all three cDNA clones were identical. There was overlap of all isolated cDNA clones with the 3' end of the Ta1.3 clone. To obtain the full-length cDNA sequence, 5'-RACE (rapid amplification of cDNA 5' ends) was performed using a kit from Invitrogen Life Technologies, according to the manufacturer's instructions. Approx. 2×10^5 plaques of the genomic library were screened using the [α -³²P]dCTP-labelled Ta1.3 clone at high stringency according to the manufacturer's instructions (Stratagene). Three positive plaques were isolated and confirmed to be identical by DNA sequencing. The whole genomic DNA was sequenced by primer walking. DNA sequencing was performed using a BigDye Terminator Cycle sequencing kit and a 373A DNA Automatic Sequencer (PerkinElmer Applied Biosystems) at the Biotechnology Center, University of Illinois at Urbana-Champaign. The whole cDNA sequence of *TgPI-PLC* was spliced with program EditView 1.0.1. The sequence alignment was performed using the ClustalW alignment program available at the Biology WorkBench 3.2 (<http://workbench.sdsc.edu/>).

Southern blot analysis

Total genomic DNA from tachyzoites was isolated by phenol extraction, digested with different restriction enzymes that cut at sites not contained within the coding region, separated on a 0.8 % agarose gel and transferred on to nylon membranes. The blot was probed with a [α -³²P]dCTP-labelled Ta1.3 probe using standard methods [19].

Expression and purification of recombinant *TgPI-PLC* (r*TgPI-PLC*)

The whole ORF (open reading frame) of *TgPI-PLC* was amplified using *T. gondii* cDNA with forward primer, 5'-GGCTAGC-

ATGGAGAGACAGACGTCTTCG-3', and reverse primer, 5'-GGCTAGCTCACACCAAGGCCCGGTGG-3', in which the underlined nucleotides are the introduced NheI sites to allow *TgPI-PLC* to be cloned into the expression vector pET28a (Novagen). PCR was performed using FastStart Taq DNA polymerase (Roche Applied Science), and PCR products were inserted into the pCR 2.1-TOPO TA vector and subcloned into pET28a vector, which was linearized with NheI and dephosphorylated with bacterial alkaline phosphatase (Invitrogen Life Technologies). The recombinant construct *TgPI-PLC/pET28a* was an in-frame fusion of *TgPI-PLC* with an N-terminal His₆ tag encoded in the vector and confirmed by DNA sequencing. The recombinant construct *TcPI-PLC/pET28a* was transformed into *E. coli* BL21-CodonPlus(DE3)-RIPL strain (Stratagene) and the transformants were inoculated into 1 litre of Luria-Bertani broth medium supplemented with 30 μ g/ml kanamycin, 50 μ g/ml chloramphenicol and 75 μ g/ml streptomycin at 37 °C. When the culture density reached a *D*₆₀₀ of 0.5, the expression of the *TgPI-PLC* gene was induced by addition of 0.25 mM IPTG (isopropyl β -D-thiogalactoside) and incubated at 16 °C for 72 h.

Unless indicated otherwise, the r*TgPI-PLC* protein was purified according to the method of Ghosh et al. [20] using the resin pre-charged with Ni²⁺. All procedures were performed at 4 °C. Briefly, the induced cultures were harvested and washed twice with cold PBS. The cell pellets were resuspended in Buffer A (0.5 M NaCl, 20 mM Hepes, 5 mM imidazole/HCl and 25 % glycerol, pH 7.9) and incubated on ice for 20 min after the addition of 10 mg/ml lysozyme. After sonication on ice (three times for 20 s each using a Branson Sonifier 450 at 15 % amplitude with 30 s intervals), the lysate was incubated with DNase and RNase for 20 min with gentle shaking to reduce the lysate viscosity. After centrifugation at 20000 g for 30 min, the supernatant was loaded into the pre-wet His•Bind Quick 900 Cartridges (Novagen) with Buffer A and was sequentially washed with Buffer A and Buffer B (0.5 M NaCl, 20 mM Hepes, 60 mM imidazole and 25 % glycerol, pH 7.9). The r*TgPI-PLC* was finally eluted with a linear gradient of imidazole (200–1000 mM) in 0.5 M NaCl, 20 mM Hepes and 25 % glycerol, pH 7.9. The eluted fractions containing PI-PLC activity were pooled, dialysed, divided into aliquots and stored at –80 °C. The purity of r*TgPI-PLC* was determined by SDS/10 % PAGE, and the protein concentration was determined using a protein assay agent (Bio-Rad Laboratories) using BSA as a standard.

Assay of enzyme activity of r*TgPI-PLC*

The purified r*TgPI-PLC* activity was measured by the release of water-soluble radioactivity from [³H]inositol-labelled PIP₂ or PI. Briefly, the substrate solutions of cold PIP₂ (Avanti Polar Lipids) and [*inositol-2-³H*(n)]PIP₂ (PerkinElmer Life Sciences) or unlabelled PI (Sigma) and [*myo-inositol-2-³H*(n)]PI (PerkinElmer Life Sciences) in organic solvent were mixed, and the solvent was thoroughly evaporated to dryness under a stream of nitrogen. The standard assay employed a reaction mixture containing 15 000–20 000 c.p.m. of [³H]PIP₂ or [³H]PI, 40 μ M unlabelled PIP₂ or PI, 0.1 % sodium deoxycholate, 50 mM Hepes/HCl (pH 7.0), 0.2 mM dithiothreitol, 2.5 mM EGTA, 3 mM MgCl₂, 0–10 mM CaCl₂ and an appropriate amount of purified r*TgPI-PLC* protein to give a final volume of 50 μ l. The free Ca²⁺ concentrations was obtained using a CaCl₂/EGTA buffer and were calculated with the MaxChelator programme Webmaxc standard (<http://www.stanford.edu/~cpatton/webmaxc/webmaxcS.htm>). The reaction was allowed to proceed at 30 °C for 20 min and was stopped by the addition of 0.5 ml of chloroform/methanol/concentrated HCl (200:100:0.6, by vol.), followed by 0.15 ml of 5 mM EGTA in 1 M HCl. The samples were mixed well through

vigorous vortex-mixing for 30 s, and subjected to centrifugation at 20 000 *g* for 5 min at room temperature (25 °C). The upper phase (aqueous) was taken and was dissolved in 5 ml of a liquid-scintillation fluid Ecolume (ICN Biomedical). After mixing thoroughly, the samples were counted in a liquid-scintillation analyser TRI-CARB 2100TR (Packard Instrument Company).

Neomycin and compound 48/80 (Sigma) were freshly prepared in sterile distilled water. U-73122 (Calbiochem) was reconstituted in chloroform, divided into small aliquots, evaporated to dryness under a stream of nitrogen and frozen at -20 °C. The aliquots were reconstituted in ethanol before use.

SDS/PAGE and Western blot analyses

The protein samples were subjected to SDS/10% PAGE, and the electrophoresed proteins were transferred on to nitrocellulose membranes using a Bio-Rad transblot apparatus. Following transfer, the membrane blots were blocked with 3% fish gelatin (Sigma) in PBS-T (PBS containing 0.1% Tween 20) at 4 °C overnight. The blots were incubated with the 1:2000 dilution of purified guinea-pig anti-*TgPI-PLC* serum at room temperature for 1 h. The blots were washed with PBS-T four times for 15 min each. After incubation with a 1:10 000 dilution of peroxidase-conjugated AffiniPure goat anti-guinea-pig IgG (H + L) antibody (Jackson ImmunoResearch Laboratories), they were washed four times for 15 min. The immunoblots were visualized on blue-sensitive X-ray films (Midwest Scientific) using an ECL[®] (enhanced chemiluminescence) detection kit (Amersham Biosciences) according to the manufacturer's instructions.

Generation and affinity-purification of antibodies

The epitope analysis of the whole *TgPI-PLC* protein sequence with Mac Vector program (Immunological Resource Center, University of Illinois at Urbana-Champaign) predicted that the 285-amino-acid polypeptide near the C-terminus corresponding to amino acids 613–907 (see Figure 1B) presented the highest antigenicity. To obtain the recombinant polypeptide antigen, the forward primer, 5'-GGAATTC^{CCCGGGTCTGAGCATTTCTC}-3' (the underlined nucleotides are an EcoRI site) and reverse primer, 5'-GCTCGAGACGCGGGATTTCGCAT-3' (the underlined nucleotides are an XhoI site) were used to amplify *TgPI-PLC* cDNA encoding amino acids 613–907 (see Figure 1C). The resulting PCR product was cloned into pET28a expression vector to create a partial *TgPI-PLC*-His₆ fusion construct allowing purification of the recombinant protein on nickel-agarose columns. The recombinant plasmid was transformed into host *E. coli* BL21(DE3) (Novagen), and overexpression of recombinant protein was obtained through induction with 1 mM IPTG at 37 °C for 4 h. The expressed protein present in inclusion bodies was purified using His•Bind Quick 900 Cartridges under denaturing conditions (6 M urea) according to the manufacturer's instructions. The eluted recombinant protein was dialysed against 0.5 M NaCl and 0.1 M NaHCO₃ (pH 8.3), and concentrated by Microcon centrifugal filter devices (Millipore). The purity of antigen protein was determined by SDS/10% PAGE.

The polyclonal antibody against *TgPI-PLC* was generated in guinea-pigs by Cocalico Biologicals according to standard protocols. Briefly, guinea-pigs were subcutaneously injected with 100 µg of antigen emulsified in Freund's complete adjuvant after pre-serum was collected. At 2, 3, 7 and 11 weeks after the initial injection, guinea-pigs were boosted with 100 µg of antigen. The final bleed serum was divided into aliquots and was stored at -80 °C. The affinity-purification of anti-*TgPI-PLC* serum was performed using CNBr-activated matrices (Sigma). Briefly, 5 mg

of purified *TgPI-PLC* antigen was coupled with CNBr-activated resin in coupling buffer (0.5 M NaCl and 0.1 M NaHCO₃, pH 8.3). After blocking with 0.2 M glycine (pH 8.0) for 3 h, the resin was extensively washed with four cycles of coupling buffer and acetate buffer (0.1 M sodium acetate and 0.5 M NaCl, pH 4.0). The anti-*TgPI-PLC* serum was diluted in PBS and was incubated directly with the coupled resin overnight at 4 °C, and the bound antibody was eluted with 0.1 M glycine (pH 2.5–3.0) and 150 mM NaCl, and immediately neutralized with 1 M Tris/HCl (pH 8.0). The fractions with higher antibody activity were pooled, dialysed against PBS overnight at 4 °C using a Slide-A-Lyzer dialysis cassette (Pierce) and concentrated with a Microcon centrifugal filter device.

Immunofluorescence microscopy

To localize *TgPI-PLC* within intracellular parasites, indirect immunofluorescence assays were performed as described previously [21]. HFF monolayers grown on coverslips in six-well plates were infected with tachyzoites (RH strain; 1 × 10⁵ cells per well) for 20 h at 37 °C. The coverslips were washed extensively with cold PBS to remove any unattached parasites, and the remaining serum was immediately fixed with 2.5% (w/v) formaldehyde and 0.02% (w/v) glutaraldehyde, freshly prepared in ice-cold PBS for 1 h. After blocking with PBS containing 1% fish gelatin, 5% goat serum, 3% BSA and 50 mM NH₄Cl, pH 7.2, for 1 h, the parasites were permeabilized with PBS containing 0.05% saponin (Sigma) and 10% (v/v) foetal bovine serum for 30 min. After washing with PBS, the parasites were stained with affinity-purified guinea-pig anti-*TgPI-PLC* antibody (at a dilution of 1:200 in PBS containing 1% BSA), and incubated with mouse monoclonal antibody against *T. gondii* SAG1 (surface antigen 1) [22] (kindly provided by Dr David Alexander from Dr John Boothroyd's laboratory, Stanford University, Stanford, CA, U.S.A.) (at a dilution of 1:3000) for 1 h. After five washings with PBS, coverslips were incubated with FITC-conjugated AffiniPure goat anti-guinea-pig IgG (H + L) at a dilution of 1:200 and Alexa Fluor[®] 546-conjugated goat anti-mouse IgG (Molecular Probes) at a dilution of 1:1000. To view the parasite nucleus, coverslips were incubated with 0.1 µg/ml DAPI (4,6-diamidino-2-phenylindole) in PBS for 10 min. Slides were then mounted with ProLong gold anti-fade reagent (Molecular Probes). Confocal images were captured with a Leica laser-scanning confocal microscope (TCS SP2) using a 63× Plan-Apo objective with NA (numerical aperture) 1.32 (Beckman Institute, University of Illinois at Urbana-Champaign).

Cell-surface biotinylation and immunoprecipitation

Freshly lysed tachyzoites were harvested and washed three times with ice-cold PBS (pH 8.0) at 2000 *g* for 10 min. The cell pellets were immediately resuspended in 1 mM sulpho-NHS-biotin (sulpho-*N*-hydroxysuccinimidobiotin) (Pierce Biotechnology) freshly prepared in 1 ml of PBS (pH 8.0). After incubating the cells at room temperature for 30 min, they were washed five times with ice-cold PBS supplemented with 100 mM glycine (pH 8.0).

For immunoprecipitation, all procedures were carried out at 4 °C. The labelled cells were lysed in RIPA (radioimmuno-precipitation analysis) buffer (150 mM NaCl, 1% Nonidet P40, 0.5% deoxycholic acid, 50 mM Tris base, pH 7.5, 0.02% sodium azide and protease inhibitor mixture Set III from Sigma) on a rocking platform with gentle agitation for 1 h. The cell lysates were clarified by centrifugation at 20 000 *g* for 20 min to remove debris, and the supernatants were pre-absorbed with Protein A-agarose (Roche Applied Science) overnight with gentle agitation. After centrifugation at 6000 *g* for 30 s, the supernatants were




Figure 1 Organization and predicted protein sequence of *TgPI-PLC*

(A) Schematic map of the *TgPI-PLC* gene locus. The relative position of exons in the genomic DNA is indicated by black boxes with numbers. The grey boxes show the 5' end flanking region, the introns and the 3' end flanking region. A Kozak translation initiation site (tcgatATGG, where the lower-case letters indicate untranslated sequence) is indicated above with a bent arrow. The isolated *TgPI-PLC* cDNA clone (5.5 kb) contains a 3.3 kb ORF. (B) Deduced amino acid sequence of the *TgPI-PLC* cDNA clone. The unique N-terminal extension and the catalytic X and Y domains are highlighted in grey. The additional two inserts between the X and Y domains are underlined. The consensus NES of *TgPI-PLC* (H²⁷⁰LHGLLRKLNQAD²⁸³) within the EF hand is underlined in white. An additional putative leucine-rich NES site (L⁵⁶⁹ELELRM⁵⁷⁵) predicted using NetNES 1.1 (<http://www.cbs.dtu.dk/services/NetNES/>) is indicated by downward-pointing triangles downstream of the X domain. The dileucine (L¹⁰⁶⁰L¹⁰⁶¹) and a mammalian sorting YXX Φ motif (Y¹⁰⁶³SRI¹⁰⁶⁶) is indicated with closed circles and diamonds respectively under the sequence at the C-terminal tail. (C) The numbers show the starting and finishing amino acid for each domain. The bold line indicates the N-terminal extension and two triangles represent the inserts in the X-Y domain linker. The peptide used to generate polyclonal antibody against *TgPI-PLC* (Antigen) is indicated above the Y domain. The protein size is not to scale. The consensus NES of the EF hand domain is compared with those of other δ -type PLCs. The important hydrophobic residues are in black boxes. Ψ represents a hydrophobic residue (isoleucine, valine or methionine); X represents any amino acid.

divided into three 0.4 ml aliquots in fresh tubes and immunoprecipitated for 4 h with guinea-pig polyclonal antibody against *TgPI-PLC*, mouse monoclonal antibody against *T. gondii* SAG1, and mouse monoclonal antibody against *E. coli* β -galactosidase respectively. Immunocomplexes were allowed to bind to Protein A-agarose overnight with gentle agitation. The agarose beads were washed sequentially, twice with RIPA buffer, twice with high-salt buffer (500 mM NaCl, 150 mM Tris base, pH 7.5, 0.1 % Nonidet P40 and 0.05 % deoxycholic acid), and once with low-salt buffer (50 mM Tris base, pH 7.5, 0.1 % Nonidet P40 and 0.05 % deoxycholic acid). The bound proteins were eluted with boiling 2 \times Laemmli sample (SDS) buffer, applied to an SDS/10 % polyacrylamide gel and transferred on to a nitrocellulose membrane (Osmonics). The blot was probed with the horseradish-peroxidase-conjugated ImmunoPure streptavidin

(Pierce Biotechnology), and the protein bands were visualized on blue-sensitive X-ray films (Midwest Scientific) using the ECL[®] detection kit described above. A similar procedure was followed to immunoprecipitate *TgPI-PLC* from *T. gondii* lysates and bacterial fractions obtained as described above to demonstrate that the antibody could precipitate the protein, which was then probed with the same antibody (at a dilution of 1:2000) following a similar protocol to the one described above.

RESULTS

Isolation of the *TgPI-PLC* gene and sequence analysis

The complete coding region of *TgPI-PLC* was established as described under the Materials and methods section, and the

translation of the ORF of 3294 bp yielded a polypeptide of 1097 amino acids with a predicted molecular mass of 121 kDa. Comparison of the *TgPI-PLC* cDNA sequence with its genomic sequence revealed that the *TgPI-PLC* gene comprised 22 exons (the size varying from 58 to 665 bp) interrupted by 21 introns (the size varying from 135 to 830 bp) (Figure 1A). The deduced amino acid sequence was analysed to identify similarities with other genes. This analysis revealed several domains characteristic of PI-PLCs (Figure 1B). Besides the catalytic X and Y domains, *TgPI-PLC* also contains an apparent N-terminal PH (pleckstrin homology) domain, an EF hand motif and a C-terminal C-2 domain (Figures 1B and 1C). *TgPI-PLC* shares a high level of sequence identity with mammalian and plant δ -type PLCs (31–35% identity). *TgPI-PLC* has an additional N-terminal extension and two insertions in the central region that are not present in other PI-PLCs and has 200–500 amino acids more than other δ -type PI-PLCs. In addition, there is a NES (nuclear export signal) within the EF hand domain (Figures 1B and 1C) and typical mammalian sorting motifs YXX Φ (Φ is an amino acid with a bulky hydrophobic side chain) (-Y¹⁰⁶³SRI¹⁰⁶⁶-) and dileucine (LL) in the C-terminal tail (Figure 1B). Comparisons of whole sequences showed only 21–25% identities with some protozoan PI-PLCs such as those from *Plasmodium falciparum* (GenBank® accession number AAN35330), *Trypanosoma cruzi* (GenBank® accession number AAD12583), *Trypanosoma brucei* (GenBank® accession number AY157307), and *Leishmania major* (genome database temporary ID number LmjF35.0040). Interestingly, multiple sequence alignments revealed that the X and Y domains of *TgPI-PLC* share higher identities with these domains of other parasite PI-PLCs (41–49% and 43–61% identities respectively). Of four parasite PI-PLCs, the X and Y domains of *P. falciparum* PI-PLC share the highest identity with those of *TgPI-PLC* (49% and 61% respectively). Southern blot analysis of parasite genomic DNA suggested that the *TgPI-PLC* gene is present as a single-copy gene in the haploid *Toxoplasma* genome (results not shown). Searches of the *T. gondii* genome database (<http://ToxoDB.org/>) in addition to the genome sequencing project and the OrthoMCL-DB (<http://orthomcl.cbil.upenn.edu>) [23] predict the presence of only one PI-PLC in *T. gondii*. This is not uncommon in unicellular organisms as, for example, *D. discoideum* [9] and *Trypanosoma cruzi* [11].

Expression, purification and catalytic activity of recombinant *TgPI-PLC*

TgPI-PLC was expressed in *E. coli* BL21-CodonPlus(DE3)-RIPL as a fusion protein with an N-terminal polyhistidine tag. Affinity chromatography on a nickel-chelated agarose column permitted simple one-step protein purification. Enzyme purity was judged by using SDS/10% PAGE with Coomassie Blue staining (Figure 2A). The recombinant *TgPI-PLC* was recognized by the anti-*TgPI-PLC* antibody (Figure 2B, lane 2). The expressed *TgPI-PLC* appeared as a protein with an approximate size of 120 kDa, which is very close to the size predicted by its amino acid sequence (121 kDa). Figure 2(B) shows Western blot analyses of crude lysates obtained from *E. coli* transformed with the *TgPI-PLC*/pET28a recombinant plasmid (lane 3) and from the non-transformed bacteria (lane 4). The purified recombinant *TgPI-PLC* was subsequently used for further characterization of the enzyme.

Optimal levels of PIP₂ hydrolysis were obtained at 30°C (Figure 3A), and between pH 7.2 and 7.5 (Figure 3B), while optimal levels of PI hydrolysis were obtained at 20°C (Figure 3A), and between pH 7.5 and 8.5 (Figure 3B). MgCl₂ slightly stimulated PIP₂ hydrolysis, but inhibited PI hydrolysis (Figure 3C). Standard




Figure 2 Expression and affinity purification of recombinant *TgPI-PLC* from *E. coli*

(A) Protein samples were separated by SDS/10% PAGE and visualized by Coomassie Brilliant Blue staining. Lane 1, standard protein size markers (MagicMark™ XP standards) with sizes given in kDa. Lane 2, nickel column-purified fraction (2.5 µg of protein/lane). The position of *TgPI-PLC* (120 kDa) is shown by the arrow. (B) Detection of *TgPI-PLC* by immunoblot using an affinity-purified polyclonal antibody against the peptide shown in Figure 1(C). Proteins were separated by SDS/10% PAGE, transferred on to nitrocellulose membranes and probed with affinity-purified anti-*TgPI-PLC* antibody (1:2000). Lane 1, protein standards (sizes are given in kDa); lane 2, recombinant *TgPI-PLC* (0.5 µg/lane) is shown by the arrow; lane 3, crude total cell lysate of *E. coli* BL21 CodonPlus(DE3)-RIPL transformed with *TgPI-PLC*/pET28a recombinant plasmid; lane 4, crude total cell lysate of non-transformed *E. coli* BL21 CodonPlus(DE3)-RIPL.

procedures were used to determine kinetic parameters. The enzyme reaction was carried out at a free Ca²⁺ concentration of 250 µM and pH 7.5. As shown in Figures 3(D) and 3(E), maximum activity was achieved at approx. 200 µM PIP₂ or PI respectively. *K_m* and *V_{max}* values were obtained using a non-linear regression fit of the data to the Michaelis–Menten equation (SigmaPlot for Windows, version 3.06). When the rate of PIP₂ and PI hydrolysis by the recombinant enzyme were measured, *K_m* values of 130 ± 33.9 and 79 ± 9.3 µM and *V_{max}* values of 0.83 ± 0.11 and 1.22 ± 0.06 µmol/mg per min respectively were calculated (Figures 3D and 3E).

The effect of free Ca²⁺ concentration was examined using both PIP₂ and PI as substrates. The enzyme activity was stimulated by free Ca²⁺ in both cases. When PI was used as a substrate, the enzyme activity increased with increasing free Ca²⁺ concentrations above 1 µM, and the activity decreased when free Ca²⁺ concentration exceeded 1 mM (Figure 3F). When PIP₂ was used as substrate, the enzyme was activated at lower Ca²⁺ concentrations and its activity increased with increasing free Ca²⁺ concentration (Figure 3F). Addition of 3 mM MgCl₂ stimulated PIP₂ hydrolysis (Figure 3F) and inhibited PI hydrolysis (Figure 3G). These results showed that *TgPI-PLC* preferred PI to PIP₂ as a substrate in the presence of high Ca²⁺ concentrations.

Effect of PI-PLC inhibitors

The effect of known PI-PLC inhibitors was also tested. Both neomycin and compound 48/80 inhibited PI and PIP₂ hydrolysis in a concentration-dependent manner, these effects being more pronounced when PI was used as substrate (Figures 4B and 4C). However, U-73122 did not significantly affect hydrolysis of either PI or PIP₂ at concentrations between 0 and 50 µM (Figure 4A).

PI-PLC activity in *T. gondii* membranes

Since a higher activity with PI rather than with PIP₂ as substrate was unusual for a PI-PLC, we investigated whether this behaviour was also observed with the native enzyme obtained from a membrane fraction of *T. gondii* tachyzoites. A crude membrane fraction was prepared as described in the Materials and methods section, and the activity was measured following a similar protocol




Figure 3 PI-PLC activity of recombinant TgPI-PLC as a function of temperature (A), medium pH (B), Mg²⁺ concentration (C), substrate concentration (D, E) and free Ca²⁺ concentration (F, G)

Experimental conditions were as described under the Materials and methods section with 250 μM free Ca²⁺ and 40 μM PIP₂ or 40 μM PI, adjusted to different temperatures (A), pH values (B), MgCl₂ concentration (C), different concentrations of PIP₂ (D) or PI (E) and 250 μM Ca²⁺, or in the same buffer with different free Ca²⁺ concentrations and 40 μM PIP₂ (F) or 40 μM PI (G), with (open symbols) or without (closed symbols) 3 mM MgCl₂. Insets in (D) and (E) represent the linear transformation, by double-reciprocal plot, of the curve. The results are representative of three experiments, each one carried out in duplicate.




Figure 4 Effect of PI-PLC inhibitors on the activity of recombinant *TgPI-PLC*

TgPI-PLC activity was measured as described in the Materials and methods section in the presence of 40 μM substrate (PI, grey bars; PIP₂, black bars) and 250 μM Ca²⁺, pH 7.5, and different concentrations of U-73122 (A), neomycin (B), and compound 48/80 (C).




Figure 5 PI-PLC activity of a *T. gondii* membrane fraction as a function of free Ca²⁺ concentration

Freshly isolated parasites were ruptured by freezing and thawing at low osmolarity, and the homogenate was centrifuged at 15 000 *g*. The pellet fraction was used to measure PI-PLC activity using 40 μM PI (A) or 40 μM PIP₂ (B) as substrate, with different free Ca²⁺ concentrations. Other experimental details were as described in the Materials and methods section. The results are representative of three experiments, each one performed in duplicate.

to that used for the recombinant enzyme. At 600 μM Ca²⁺, PI-PLC activity was higher when PI was used as substrate (160.5 ± 2.1 with PI and 30.5 ± 7.7 pmol/min per mg of protein with PIP₂ as substrate respectively) and the inhibitor U-73122 partially inhibited PIP₂ hydrolysis (42 ± 5%), but not PI hydrolysis (7 ± 3%). Figure 5 shows that, as occurs with the recombinant enzyme (Figures 3F and 3G), although Ca²⁺ stimulated PI-PLC activity with

both PI (Figure 5A) and PIP₂ (Figure 5B) as substrate, the activity was much higher when PI was the substrate.

Localization of *TgPI-PLC*

To investigate the subcellular localization of *TgPI-PLC*, polyclonal antibodies were raised in a guinea-pig against an antigenic polypeptide (amino acids 613–907, shown in Figure 1C) and were purified by affinity chromatography. These antibodies gave a strong reaction with the recombinant protein as demonstrated by Western blot analysis (Figure 2B), while no detectable band was observed using pre-immune serum (results not shown). The localization of *TgPI-PLC* was determined by indirect immunofluorescence microscopy using the affinity-purified anti-*TgPI-PLC* antibodies. HFFs infected with tachyzoites were fixed and permeabilized with saponin before antibody binding. *TgPI-PLC* was detected in the plasma membrane of tachyzoites, but not in the host cells (Figure 6E) and co-localized with SAG1 (Figure 6F), a known plasma membrane marker [22]. No detectable signal was observed when pre-immune serum was used (results not shown). Similar results were obtained when extracellular tachyzoites were treated in a similar way (Figure 6A). *TgPI-PLC* was also shown to co-localize with SAG1 (Figures 6B and 6C).

To investigate whether *TgPI-PLC* is located in the extracellular phase of the plasma membrane, recently released tachyzoites of




Figure 6 Distribution of *TgPI-PLC* in intracellular and extracellular tachyzoites

Cells were permeabilized with 0.05% saponin for 30 min. The Figure shows the co-localization of *TgPI-PLC* (A, E) with SAG1 (B, F) in the plasma membrane. (C) and (G) show the overlap of (A) and (B), and (E) and (F) respectively. (D) and (H) are phase images. DAPI (4,6-diamidino-2-phenylindole) staining is shown in (H). Scale bar, 5 μm.




Figure 7 Biotinylation of cell-surface proteins in tachyzoites

Upper panel, tachyzoites of the 2F1 strain were incubated with 2 mM sulho-NHS-biotin for 30 min. After lysis of the cells with RIPA buffer, the lysates were immunoprecipitated by the affinity-purified anti-*TgPI-PLC* polyclonal antibody, and the immunoprecipitates were subjected to Western blot analysis. Detection of biotinylation was carried out using streptavidin–peroxidase conjugate and ECL[®]. No band was detected in the immunoprecipitates with anti-PI-PLC (lane 1). Lane 2 shows a positive control with anti-SAG1 antibody instead of anti-*TgPI-PLC* antibody for immunoprecipitation. Lane 3 shows a negative control with anti- β -galactosidase antibody for immunoprecipitation. Migration of molecular-mass standards (in kDa) is shown to the left of the gels. Lower panel, the positive control experiment shows that the anti-*TgPI-PLC* antibody can immunoprecipitate both the native PLC from *T. gondii* (left-hand lane) and the recombinant *TgPI-PLC* (right-hand lane), as probed with the guinea-pig anti-*TgPI-PLC* antibody. The position of a 120 kDa protein is indicated.

the 2F1 strain (expressing β -galactosidase) were analysed following biotinylation. The surface proteins of tachyzoites were labelled with sulho-NHS-biotin, a reagent that couples biotin to lysine residues of exposed proteins. The cells were incubated with the reagent and lysed, and *TgPI-PLC* was immunoprecipitated with the polyclonal antibody. As controls, the lysates were also immunoprecipitated with antibodies against β -galactosidase, which is cytosolic, or with monoclonal antibodies against SAG1, which is GPI-anchored to the plasma membrane and therefore exposed to the outer surface of the cells [22]. The precipitated proteins were electrophoresed and blotted, and biotinylated proteins were visualized using peroxidase-conjugated streptavidin and ECL[®]. A 30 kDa polypeptide corresponding to SAG1 was detected when lysates were immunoprecipitated with anti-SAG1 antibodies (Figure 7, upper panel, lane 2), while no bands were detected with the negative control immunoprecipitated with β -galactosidase antibodies (Figure 7, upper panel, lane 3) or with the lysates immunoprecipitated with anti-*TgPI-PLC* antibodies (Figure 7, upper panel, lane 1). The lower panel of Figure 7 shows the immunoprecipitation by the anti-*TgPI-PLC* antibody of the native PI-PLC from a *T. gondii* lysate (left-hand lane) and of the recombinant *TgPI-PLC* (right-hand lane), as probed with the same antibody. Taken together, these results indicate that *TgPI-PLC* is not localized on the outer surface of tachyzoites.

DISCUSSION

In the present work, we have demonstrated that a gene, *TgPI-PLC*, encoding a functional PI-PLC, is present in the *T. gondii* genome. We have also shown that the *T. gondii* enzyme has several peculiarities that distinguish it from other known PI-PLCs. Both the recombinant and the native enzyme have PI- and PIP₂-hydrolysing activities. It is interesting to note that the

PI-hydrolysing activity was almost 10-fold higher than the PIP₂-hydrolysing activity in the absence of Mg²⁺ (Figure 3C). In the presence of 6 mM MgCl₂, however, the PIP₂-hydrolysing activity was twice as high as the PI-hydrolysing activity (Figure 3C). As shown in Figure 3(F), between 1 and 10 μ M Ca²⁺ and in the presence of millimolar Mg²⁺ concentrations, the enzyme hydrolyses mainly PIP₂. It is possible that *TgPI-PLC* functions mainly as a PIP₂-hydrolysing enzyme under the physiological millimolar concentrations of Mg²⁺ that are present inside the cell. However, we cannot rule out a preferential hydrolysis of PI if the enzyme reaches the extracellular medium, which is rich in Ca²⁺ and poor in Mg²⁺.

The temperature is also another important variable, since it has been shown that Ca²⁺-stimulated microneme secretion is temperature-sensitive [21]. PIP₂-hydrolysing activity was higher at the physiological temperature to which tachyzoites are exposed (37°C), while the PI-hydrolysing activity was higher at 20°C. Furthermore, at Ca²⁺ levels below 1 μ M, *rTgPI-PLC* had high activity with PIP₂ and negligible activity with PI as substrate respectively. The PI-hydrolysing activity increased at Ca²⁺ concentrations above 10 μ M and reached its maximum activity at 100–200 μ M Ca²⁺. Taken together, these results suggest that *TgPI-PLC* prefers PIP₂ as substrate under the physiological conditions that are present in the parasite. However, under certain conditions, such as the high Ca²⁺ concentration induced by treatment of *T. gondii*-infected cells with Ca²⁺ ionophore A23187, a process known to stimulate parasite egress [16], the PI-hydrolysing activity could be more relevant. In this regard, the escape of *Listeria monocytogenes* [24] and *Trypanosoma cruzi* [25] from their parasitophorous vacuoles are known to be mediated by PLCs (phospholipase C), and such a role has also been postulated in the case of *T. gondii* on the basis of inhibitor studies [16].

Immunofluorescence results suggest that *TgPI-PLC* is predominantly localized in the internal leaflet of the plasma membrane (Figures 6A and 6E). This is supported by surface biotinylation studies (Figure 7).

Sequence comparisons of *TgPI-PLC* with other PI-PLCs suggest that it is most closely related to the mammalian δ isoform and to PI-PLCs found in yeasts, *D. discoideum* and plants in terms of sequence identity and arrangement of conserved domains. In addition, among other lower eukaryotic and mammalian PI-PLCs, *TgPI-PLC* is one of the largest, with 1097 amino acids. When compared with other δ -type PI-PLCs, *TgPI-PLC* has an extended N-terminal region and two insertions between the X and Y domains. However, *TgPI-PLC* conserves most of the amino acid residues that have been found, in mammalian PI-PLC- δ 1 [26], to be in contact with IP₃ and Ca²⁺ in the catalytic domains (His⁴²⁰, Asn⁴²¹, Glu⁴⁵⁰, Asp⁴⁵², His⁴⁶⁵, Glu⁵⁰², Lys⁵⁴⁷, Lys⁵⁴⁹, Ser⁸¹⁴, Arg⁸⁴¹ and Tyr⁸⁴³) (Figure 1B). This conservation of amino acid residues that are important for substrate and Ca²⁺ binding explains the similar characteristics and Ca²⁺ requirement of *TgPI-PLC* as compared with mammalian δ -type PI-PLCs (Figure 3). In addition, similar to the PI-PLC- δ isoenzymes from other organisms, *TgPI-PLC* contains an EF hand motif upstream of the X domain as well as an apparent PH domain at the N-terminal region. However, in contrast with all δ -type PI-PLCs reported to date [26–28], it has a short C-terminal extension following the C2 domain. The presence of unusual clusters of negatively charged and mixed-charged amino acids between the X and Y catalytic domains is not common in PI-PLCs of lower eukaryotes or in mammalian δ - or γ -type PI-PLCs. However, mammalian β -type PI-PLCs also contain highly charged clusters of amino acids between the X and Y domain. This is essential for activation by $\beta\gamma$ subunits of G-proteins. *D. discoideum* δ -type PI-PLC is also postulated to be activated in this manner [29].

The presence of NESs approx. 14-amino-acids long and rich in leucine, suggests the possibility that the enzyme is imported to the nucleus and that this sequence is probably responsible for its export from this organelle. This has been demonstrated to occur with the mammalian PLC- δ 1 [30]. Blocking its NES-dependent nuclear export results in its nuclear accumulation, although it is not known by which mechanism the enzyme is transported into the nucleus [30].

In conclusion, TgPI-PLC has distinct peculiarities when compared with mammalian PI-PLCs, but its sequence and the organization of its different domains are similar to those of δ -type isoenzymes. The meaning of these differences in the physiological context of host–parasite interaction is being explored at present.

The monoclonal antibody against *E. coli* β -galactosidase was developed by Joshua Sanes and was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD (National Institute of Child Health and Human Development) and maintained by The University of Iowa, Department of Biological Sciences, Iowa City, IA 52242, U.S.A. We thank David Alexander and John Boothroyd (Stanford University) for the monoclonal antibody against SAG1, L. David Sibley (Washington University School of Medicine) for *T. gondii* 2F1 strain, Maria Laura Salto for help in measuring PLC activity, Peter Rohloff for help with immunofluorescence imaging, and Linda Brown for her assistance with the growth of *T. gondii*. This work was supported in part by U.S. National Institutes of Health Grant AI-43614 to S. N. J. M. This investigation was conducted in part in a facility constructed with support from Research Facility Improvement Grant Number C06 RR16515-01 from the National Center for Research Resources, U.S. National Institutes of Health.

REFERENCES

- Berridge, M. J. (1987) Inositol trisphosphate and diacylglycerol: two interacting second messengers. *Annu. Rev. Biochem.* **56**, 159–193
- Nishizuka, Y. (1988) The molecular heterogeneity of protein kinase C and its implications for cellular regulation. *Nature (London)* **334**, 661–665
- Nakahara, M., Shimozawa, M., Nakamura, Y., Irino, Y., Morita, M., Kudo, Y. and Fukami, K. (2005) A novel phospholipase C, PLC γ 2, is a neuron-specific isozyme. *J. Biol. Chem.* **280**, 29128–29134
- Irvine, R. (1996) Phospholipid signalling: taking stock of PI-PLC. *Nature (London)* **380**, 581–583
- Hodson, E. A., Ashley, C. C., Hughes, A. D. and Lymn, J. S. (1998) Regulation of phospholipase C- δ by GTP-binding proteins-rhoA as an inhibitory modulator. *Biochim. Biophys. Acta* **1403**, 97–101
- Flick, J. S. and Thorner, J. (1993) Genetic and biochemical characterization of a phosphatidylinositol-specific phospholipase C in *Saccharomyces cerevisiae*. *Mol. Cell. Biol.* **13**, 5861–5876
- Payne, W. E. and Fitzgerald-Hayes, M. (1993) A mutation in PLC1, a candidate phosphoinositide-specific phospholipase C gene from *Saccharomyces cerevisiae*, causes aberrant mitotic chromosome segregation. *Mol. Cell. Biol.* **13**, 4351–4364
- Yoko-o, T., Matsui, Y., Yagisawa, H., Nojima, H., Uno, I. and Toh-e, A. (1993) The putative phosphoinositide-specific phospholipase C gene, PLC1, of the yeast *Saccharomyces cerevisiae* is important for cell growth. *Proc. Natl. Acad. Sci. U.S.A.* **90**, 1804–1808
- Drayer, A. L. and van Haastert, P. J. (1992) Molecular cloning and expression of a phosphoinositide-specific phospholipase C of *Dictyostelium discoideum*. *J. Biol. Chem.* **267**, 18387–18392
- Bominaar, A. A. and Van Haastert, P. J. (1994) Phospholipase C in *Dictyostelium discoideum*: identification of stimulatory and inhibitory surface receptors and G-proteins. *Biochem. J.* **297**, 189–193
- Furuya, T., Kashuba, C., Docampo, R. and Moreno, S. N. (2000) A novel phosphatidylinositol-phospholipase C of *Trypanosoma cruzi* that is lipid modified and activated during trypomastigote to amastigote differentiation. *J. Biol. Chem.* **275**, 6428–6438
- Salto, M. L., Furuya, T., Moreno, S. N., Docampo, R. and de Lederkremer, R. M. (2002) The phosphatidylinositol-phospholipase C from *Trypanosoma cruzi* is active on inositolphosphoceramide. *Mol. Biochem. Parasitol.* **119**, 131–133
- Okura, M., Fang, J., Salto, M. L., Singer, R. S., Docampo, R. and Moreno, S. N. (2005) A lipid-modified phosphoinositide-specific phospholipase C (TcPI-PLC) is involved in differentiation of trypomastigotes to amastigotes of *Trypanosoma cruzi*. *J. Biol. Chem.* **280**, 16235–16243
- Carruthers, V. B., Moreno, S. N. and Sibley, L. D. (1999) Ethanol and acetaldehyde elevate intracellular $[Ca^{2+}]$ and stimulate microneme discharge in *Toxoplasma gondii*. *Biochem. J.* **342**, 379–386
- Lovett, J. L., Marchesini, N., Moreno, S. N. and Sibley, L. D. (2002) *Toxoplasma gondii* microneme secretion involves intracellular Ca^{2+} release from inositol 1,4,5-triphosphate (IP_3)/ryanodine-sensitive stores. *J. Biol. Chem.* **277**, 25870–25876
- Moudy, R., Manning, T. J. and Beckers, C. J. (2001) The loss of cytoplasmic potassium upon host cell breakdown triggers egress of *Toxoplasma gondii*. *J. Biol. Chem.* **276**, 41492–41501
- Moreno, S. N. and Zhong, L. (1996) Acidocalcisomes in *Toxoplasma gondii* tachyzoites. *Biochem. J.* **313**, 655–659
- Kissinger, J. C., Gajria, B., Li, L., Paulsen, I. T. and Roos, D. S. (2003) ToxoDB: accessing the *Toxoplasma gondii* genome. *Nucleic Acids Res.* **31**, 234–236
- Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989) *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor
- Ghosh, S., Pawelczyk, T. and Lowenstein, J. M. (1997) Phospholipase C isoforms δ_1 and δ_3 from human fibroblasts: high-yield expression in *Escherichia coli*, simple purification, and properties. *Protein Expression Purif.* **9**, 262–278
- Carruthers, V. B., Giddings, O. K. and Sibley, L. D. (1999) Secretion of micronemal proteins is associated with *Toxoplasma* invasion of host cells. *Cell. Microbiol.* **1**, 225–235
- Burg, J. L., Perelman, D., Kasper, L. H., Ware, P. L. and Boothroyd, J. C. (1988) Molecular analysis of the gene encoding the major surface antigen of *Toxoplasma gondii*. *J. Immunol.* **141**, 3584–3591
- Chen, F., Mackey, A. J., Stoeckert, C. J. and Roos, D. S. (2006) OrthoMCL-DB: querying a comprehensive multi-species collection of ortholog groups. *Nucleic Acids Res.* **34**, D363–D368
- Marquis, H. and Hager, E. J. (2000) pH-regulated activation and release of a bacteria-associated phospholipase C during intracellular infection by *Listeria monocytogenes*. *Mol. Microbiol.* **35**, 289–298
- Hall, B. F., Webster, P., Ma, A. K., Joiner, K. A. and Andrews, N. W. (1992) Desialylation of lysosomal membrane glycoproteins by *Trypanosoma cruzi*: a role for the surface neuraminidase in facilitating parasite entry into the host cell cytoplasm. *J. Exp. Med.* **176**, 313–325
- Essen, L. O., Perisic, O., Cheung, R., Katan, M. and Williams, R. L. (1996) Crystal structure of a mammalian phosphoinositide-specific phospholipase C δ . *Nature (London)* **380**, 595–602
- Paterson, H. F., Savopoulos, J. W., Perisic, O., Cheung, R., Ellis, M. V., Williams, R. L. and Katan, M. (1995) Phospholipase C δ_1 requires a pleckstrin homology domain for interaction with the plasma membrane. *Biochem. J.* **312**, 661–666
- Yagisawa, H., Sakuma, K., Paterson, H. F., Cheung, R., Allen, V., Hirata, H., Watanabe, Y., Hirata, M., Williams, R. L. and Katan, M. (1998) Replacements of single basic amino acids in the pleckstrin homology domain of phospholipase C- δ 1 alter the ligand binding, phospholipase activity, and interaction with the plasma membrane. *J. Biol. Chem.* **273**, 417–424
- Brazill, D. T., Lindsey, D. F., Bishop, J. D. and Gomer, R. H. (1998) Cell density sensing mediated by a G protein-coupled receptor activating phospholipase C. *J. Biol. Chem.* **273**, 8161–8168
- Ochocka, A. M. and Pawelczyk, T. (2003) Isozymes δ of phosphoinositide-specific phospholipase C and their role in signal transduction in the cell. *Acta Biochim. Pol.* **50**, 1097–1110